Cell and Gene Outsourcing

  1. When High-Stakes ADC Decisions Can't Wait for More Material or Better Data 7/21/2026

    Learn how a material-sparing analytical workflow can generate reliable data, reduce dependence on calibration assays, and support faster, more confident candidate evaluation.

  2. LVV Lot Release Testing 7/20/2026

    Lentiviral vector therapies present distinct testing challenges. Accessing structured release testing panels ensures rigorous safety, reliable lot disposition, and regulatory compliance.

  3. Human Derived Cell Substrate Characterization 7/20/2026

    Safe human cell line use needs key safety, identity, and purity testing steps at each cell bank stage. Robust assay plans assure full regulatory compliance, high safety, and product quality.

  4. AAV Lot Release Testing 7/20/2026

    AAV lot release testing evolves from bulk harvest through drug product release to guarantee safety, purity, and potency. Structured testing strategies ensure compliance and consistency.

  5. Monoclonal Antibody Lot Release Testing For CHO Cell–Derived Products 7/20/2026

    Biologic lot testing spans bulk harvest to final stability. Core panels check purity, safety, identity, and potency to ensure compliance, low risk, and high product quality across production.

  6. CHO Cell Line Characterization 7/20/2026

    Biologic lot testing spans bulk harvest to final stability. Core panels check purity, safety, identity, and potency to ensure compliance, low risk, and high product quality across production.

  7. What's Next In Biopharma And CGT? 7/20/2026

    Evaluating single-use bioprocess modalities requires aligning capital strategy, standardized extractables frameworks, and updated biocompatibility testing to ensure compliance.

  8. DNA Quality As A Manufacturing Variable: What Sponsors Need To Know 7/20/2026

    Traditional plasmid DNA manufacturing introduces biological impurities and structural variability that lower viral titers. Transitioning to cell-free synthetic DNA platforms ensures sequence fidelity.

  9. POSTmark Autologous: The Case For Manufacturing Continuity 7/20/2026

    Bridging the gap between early cell therapy development and clinical manufacturing requires operational continuity. Standardizing automated equipment eliminates technology transfer friction.

  10. CAR-T Manufacturing: Centralized Vs. Hybrid Models 7/20/2026

    Choosing between centralized and hybrid CAR-T manufacturing models impacts scalability, logistics, and timelines. Centralized models maximize control, while hybrid networks reduce vein-to-vein times.